Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas

NCT01158651 is registered in ClinicalTrials.gov with University of Alabama at Birmingham as lead sponsor.

NCT NCT01158651
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01158651 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of RAD001 (Everolimus) for Children With NeurF1 and Chemotherapy-Refractory Radiographic Progressive Low Grade Gliomas
Lead sponsor
University of Alabama at Birmingham
Phase
Phase 2
Overall status
Completed
Start date
July 10, 2010
Completion date
October 26, 2017
Enrollment
23 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

glioma